Navigation Links
NBTY Announces Agreement to Purchase Leiner Health Products
Date:6/10/2008

RONKONKOMA, N.Y., June 10 /PRNewswire-FirstCall/ -- NBTY, Inc. (NYSE: NTY) (http://www.NBTY.com), a leading global manufacturer and marketer of nutritional supplements, today announced it submitted the best and highest bid at an auction held on June 9, 2008 for the purchase of substantially all of the assets of Leiner Health Products, Inc. ("Leiner").

In connection with the auction, NBTY entered into an amended and restated Asset Purchase Agreement (the "Agreement") for the purchase of substantially all of the assets of Leiner for approximately $371 million plus assumption of certain liabilities. The Agreement provides for a downward purchase price adjustment if the amount of actual working capital at the closing is less than $110 million, and for an upward purchase price adjustment if the amount of actual working capital at closing is greater than $110 million.

The Agreement is subject to the approval of the bankruptcy court presiding over Leiner's chapter 11 bankruptcy proceedings. The purchase transaction is also subject to regulatory and other customary approvals and customary closing conditions. NBTY expects to consummate the acquisition by no later than September 2008.

NBTY Chairman and CEO, Scott Rudolph, said: "The Leiner acquisition reflects our ongoing efforts to better meet the needs of our customers by providing them with the highest quality service and continuous product supply. We continue to seek acquisitions which will enhance our position as the worldwide leader in the nutritional supplement industry and further our ongoing efforts to generate growth and increase shareholder value."

ABOUT NBTY

NBTY is a leading global vertically integrated manufacturer, marketer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. Under a number of NBTY and third party brands, the Company offers over 22,000 products, including products marketed by the Company's Nature's Bounty(R) (http://www.NaturesBounty.com), Vitamin World(R) (http://www.VitaminWorld.com), Puritan's Pride(R) (http://www.Puritan.com), Holland & Barrett(R) (http://www.HollandAndBarrett.com), Rexall(R) (http://www.Rexall.com), Sundown(R) (http://www.SundownNutrition.com), MET-Rx(R) (http://www.MetRX.com), Worldwide Sport Nutrition(R) (http://www.SportNutrition.com), American Health(R) (http://www.AmericanHealthUS.com), GNC (UK)(R) (http://www.GNC.co.uk), DeTuinen(R) (http://www.DeTuinen.nl), LeNaturiste(TM) (http://www.LeNaturiste.com), SISU(R) (http://www.SISU.com), Solgar(R) (http://www.Solgar.com), Good 'n' Natural(R) (http://www.goodnnatural.com), Home Health(TM) (http://www.homehealthus.com) and Ester-C(R) (http://www.Ester-C.com) brands.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terminology such as "subject to," "believe," "expects," "plan," "project," "estimate," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although all of these forward looking statements are believed to be reasonable, they are inherently uncertain. Factors which may materially affect such forward-looking statements include: (i) slow or negative growth in the nutritional supplement industry; (ii) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest or disruption of mail service; (iii) adverse publicity regarding nutritional supplements; (iv) inability to retain customers of companies (or mailing lists) recently acquired; (v) increased competition; (vi) increased costs; (vii) loss or retirement of key members of management; (viii) increases in the cost of borrowings and/or unavailability of additional debt or equity capital; (ix) unavailability of, or inability to consummate, advantageous acquisitions in the future, including those that may be subject to bankruptcy approval or the inability of NBTY to integrate acquisitions into the mainstream of its business; (x) changes in general worldwide economic and political conditions in the markets in which NBTY may compete from time to time; (xi) the inability of NBTY to gain and/or hold market share of its wholesale and/or retail customers anywhere in the world; (xii) unavailability of electricity in certain geographical areas; (xiii) the inability of NBTY to obtain and/or renew insurance and/or the costs of the same; (xiv) exposure to and expense of defending and resolving product liability and intellectual property claims and other litigation; (xv) the ability of NBTY to successfully implement its business strategy; (xvi) the inability of NBTY to manage its retail, wholesale, manufacturing and other operations efficiently; (xvii) consumer acceptance of NBTY's products; (xviii) the inability of NBTY to renew leases for its retail locations; (xix) the inability of NBTY's retail stores to attain or maintain profitability; (xx) the absence of clinical trials for many of NBTY's products; (xxi) sales and earnings volatility and/or trends for the Company and its market segments; (xxii) the efficacy of NBTY's Internet and on-line sales and marketing strategies; (xxiii) fluctuations in foreign currencies, including the British pound, the Euro and the Canadian dollar; (xxiv) import-export controls on sales to foreign countries; (xxv) the inability of NBTY to secure favorable new sites for, and delays in opening, new retail and manufacturing locations; (xxvi) introduction of and compliance with new federal, state, local or foreign legislation or regulation or adverse determinations by regulators anywhere in the world (including the banning of products) and more particularly Good Manufacturing Practices in the United States, the Food Supplements Directive and Traditional Herbal Medicinal Products Directive in Europe and Section 404 requirements of the Sarbanes-Oxley Act of 2002; (xxvii) the mix of NBTY's products and the profit margins thereon; (xxviii) the availability and pricing of raw materials; (xxix) risk factors discussed in NBTY's filings with the U.S. Securities and Exchange Commission; (xxx) adverse effects on NBTY as a result of increased energy prices and potentially reduced traffic flow to NBTY's retail locations; (xxxi) adverse tax determinations; (xxxii) the loss of a significant customer of the Company; (xxxiii) potential investment losses as a result of liquidity conditions; and (xxxiv) other factors beyond the Company's control.

Readers are cautioned not to place undue reliance on forward-looking statements. NBTY cannot guarantee future results, trends, events, levels of activity, performance or achievements. NBTY does not undertake and specifically declines any obligation to update, republish or revise forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events.

Consequently, such forward-looking statements should be regarded solely as NBTY's current plans, estimates and beliefs.


'/>"/>
SOURCE NBTY, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CorVel Announces Record Earnings
2. SUA Insurance Company Announces Partnership With American Safety Indemnity Company
3. WellPoint Announces Appearance at Upcoming Conference
4. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
5. Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer
6. Mylan Announces Final FDA Approval for Zaleplon Capsules
7. PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative
8. Senetek PLC Announces Key Personnel Appointments
9. QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million
10. Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled,
11. Universal Health Realty Income Trust Announces Dividend Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: